Publications

Detailed Information

Spontaneous reporting of adverse drug events by Korean Regional Pharmacovigilance Centers

DC Field Value Language
dc.contributor.authorShin, Yoo Seob-
dc.contributor.authorLee, Yong-Won-
dc.contributor.authorChoi, Young Hwa-
dc.contributor.authorPark, Byungjoo-
dc.contributor.authorChoi, Sung-Kyu-
dc.contributor.authorPark, Jung-Won-
dc.contributor.authorHong, Chein-Soo-
dc.contributor.authorKim, Eung-Gyu-
dc.contributor.authorJee, Young Koo-
dc.date.accessioned2012-06-08T07:23:04Z-
dc.date.available2012-06-08T07:23:04Z-
dc.date.issued2009-10-
dc.identifier.citationPHARMACOEPIDEMIOLOGY AND DRUG SAFETY; Vol.18 10; 910-915ko_KR
dc.identifier.issn1053-8569-
dc.identifier.urihttps://hdl.handle.net/10371/76914-
dc.description.abstractPurpose Patterns of prescriptions are markedly influenced by regional disease entities, medical education, culture, economic status, and available pharmaceutical companies. Features of adverse drug reactions (ADRs) may vary in different countries. In this study, we analyzed the causative drugs and clinical manifestations of spontaneously reported ADRs in Korea. Methods Six Korean Regional Pharmacovigilance Centers collected 1418 cases of spontaneously reported adverse drug events (ADES) by doctors, pharmacists, and nurses, and the clinical features and causative drugs were evaluated. The data were collected from general hospitals (76.5%), primary clinics, and pharmacies (23.5%). Results Based upon the World Health Organization (WHO)-Uppsala Monitoring Center criteria (certain-13.7%, probable-46.1%, possible-32.1%), 91.9% of the collected events were suspected to be ADRs and 15.8% of patients experienced serious ADRs. The most prevalent causative drugs were antibiotics (31.6%), followed by contrast dyes (14.0%), non-steroidal anti-inflammatory drugs (NSAIDs) (11.1%), anti-psychotics (5.4%), anti-convulsants (5.2%), cardiovascular agents (4.8%), anti-neoplastics (4.6%), and opiates and non-opiate pain killers (3.5%). Among the antibiotics, cephalosporins (8.1%) were the most common, followed by anti-tuberculosis agents (5.7%), quinolones (4.0%), vancomycin (3.1%), and penicillin (2.8%). The most common side effect was skin manifestations, which were seen in 42% of the patients, followed by neurologic manifestations (14%), gastrointestinal involvements (12.9%), generalized reactions (9.4%), and respiratory involvements (4.5%). Conclusion Antibiotics, contrast dyes, and NSAIDs were the most common causative drugs for ADRs, which reflects the prescription pattern and the prevalence of diseases in Korea. These data may be useful in establishing a Korean pharmacovigilance system. Copyright (C) 2009 John Wiley & Sons, Ltd.ko_KR
dc.language.isoenko_KR
dc.publisherJOHN WILEY & SONS LTDko_KR
dc.subjectadverse drug reactionko_KR
dc.subjectRegional Pharmacovigilance Centerko_KR
dc.subjectspontaneous reportingko_KR
dc.titleSpontaneous reporting of adverse drug events by Korean Regional Pharmacovigilance Centersko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor신유섭-
dc.contributor.AlternativeAuthor이용원-
dc.contributor.AlternativeAuthor최영화-
dc.contributor.AlternativeAuthor박병주-
dc.contributor.AlternativeAuthor지영구-
dc.contributor.AlternativeAuthor최성규-
dc.contributor.AlternativeAuthor김응규-
dc.contributor.AlternativeAuthor박정원-
dc.contributor.AlternativeAuthor홍천수-
dc.identifier.doi10.1002/pds.1796-
dc.citation.journaltitlePHARMACOEPIDEMIOLOGY AND DRUG SAFETY-
dc.description.citedreferenceEliasson E, 2006, BRIT MED J, V332, P1163-
dc.description.citedreferenceCamargo AL, 2006, EUR J CLIN PHARMACOL, V62, P143, DOI 10.1007/s00228-005-0086-7-
dc.description.citedreferenceClassen DC, 2005, QUAL SAF HEALTH CARE, V14, P221, DOI 10.1136/qshc.2002.002972-
dc.description.citedreferenceCLASSEN DC, 2005, QUAL SAF HEALTH CARE, V14, P225-
dc.description.citedreferenceStricker BHC, 2004, BRIT MED J, V329, P44-
dc.description.citedreferenceCHOI JH, 2004, KOREAN J MED, V67, P290-
dc.description.citedreferenceThong BYH, 2003, ANN ALLERG ASTHMA IM, V90, P342-
dc.description.citedreferenceLacoste-Roussillon C, 2001, CLIN PHARMACOL THER, V69, P458-
dc.description.citedreferenceDEMOLY P, 2001, CURR OPIN ALLERGY CL, V1, P305-
dc.description.citedreferenceEdwards IR, 2000, LANCET, V356, P1255-
dc.description.citedreferenceGandhi TK, 2000, J GEN INTERN MED, V15, P149-
dc.description.citedreferenceBates DW, 1999, ARCH INTERN MED, V159, P2553-
dc.description.citedreferenceRoughead EE, 1998, MED J AUSTRALIA, V168, P405-
dc.description.citedreferenceLazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200-
dc.description.citedreferenceHunziker T, 1997, ALLERGY, V52, P388-
dc.description.citedreferenceClassen DC, 1997, JAMA-J AM MED ASSOC, V277, P301-
dc.description.citedreferenceBATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29-
dc.description.citedreferenceRAWLINS MD, 1995, J ROY COLL PHYS LOND, V29, P41-
dc.description.citedreferenceLEAPE LL, 1991, NEW ENGL J MED, V324, P377-
dc.description.citedreferenceBERRY LL, 1988, AM J HOSP PHARM, V45, P1534-
dc.description.citedreferenceFAICH GA, 1986, NEW ENGL J MED, V314, P1589-
dc.description.citedreferenceJICK H, 1984, J ALLERGY CLIN IMMUN, V74, P555-
dc.description.tc4-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share